Celine Halioua on Loyal, Dog Longevity Drugs, and the Path to Human Lifespan Extension
"By the time you're done running a human lifespan extension trial, your patent would be expired," says Celine Halioua, founder and CEO of Loyal. That's why the company exists. Dogs age the way humans do — they develop dementia, Parkinson's, cancer — and a dog drug costs roughly $50 million to bring to approval, on a timeline short enough to keep the patent. Halioua has spent six years proving the path works: $250 million raised, two FDA efficacy approvals, a Series C closed.
This episode of the Village Global Podcast, hosted by Sam Kirschner, VP at Village Global, covers what it looks like to build a company around a regulatory pathway that had never been used before.
Listen to the full episode on Apple Podcasts, Spotify, YouTube, or wherever you like to listen.
For insights from across the Village Global Network straight to your feed, follow us on X, LinkedIn, Youtube, Instagram, and TikTok.
Key Insights
A human lifespan extension trial takes long enough that the patent expires before results come in
Drug discovery and development can be more of a business problem than a biology problem sometimes. The biology of human aging is tractable. The economics are what make it impossible to develop a drug for it.
A human lifespan extension trial would take decades to run. Patent protection would expire before results came in, eliminating the ROI that justifies the investment. Multiply the study cost by the ~9% success rate for human drugs (inflated by decades of testing in mice that don't age the way humans do) and no rational drug company runs the trial. "Running a lifespan extension study in humans would take forever, it would cost billion-plus dollars," Halioua says. "By the time you're done running it, your patent would be expired."
Dogs sidestep the structural problems. Dog drug development costs roughly $50 million all-in. Dog lifespans are short enough to generate clinical trial results in observable time. The veterinary market is cash-pay, so consumers invest in preventative care without the insurance and PBM friction that makes human preventative medicine economically unworkable. Drug companies built clinical trial infrastructure around acute disease and never had reason to design it for something as slow as aging. A small company can fund the entire lifecycle privately and commercialize without a pharma acquirer.
Dogs age like humans, mice don't.
The standard path from drug discovery to human trial runs through mice. It has also produced decades of compounds that cured diseases in rodents and failed in humans. The mismatch is biological: mice don't naturally develop the diseases of aging.
Dogs do. "A dog naturally develops dementia. They develop Parkinson's, they develop cancer like we do. They develop osteoarthritis like we do," Halioua says. That's stronger evidence than a mouse model produces and Halioua estimates human trial success probability shifts from ~9% to roughly 40% with compelling dog data behind it. At that probability, a billion-dollar human longevity trial is worth running.
The milestone that closes risk for you and the milestone that closes risk for your investor are not the same event
Loyal had efficacy data a year and a half before the FDA issued the formal approval letter. During that gap, Halioua understood what the data meant, but her investors couldn't independently verify it.
"Your average generalist investor cannot underwrite [the data]. They can't come to that same conclusion as me without a lot of work," she says. Receiving theformal FDA letter, which was two pages and a straightforward read, closed the diligence question. "They can read that." The data was an internal milestone. The letter was a fundraising milestone.
Map milestones twice: once for scientific progress, once for investor legibility. Loyal's Series C was built around three closed risks — efficacy, safety, and the near-elimination of biological failure modes. What remained was manufacturing: difficult and capital-intensive, but solvable. "It really in almost every universe is when do we get this drug approved," Halioua says. The shift from "if" to "when," is what investors were underwriting.
Healthy parents are career capital most people can't afford to lose
Longevity discourse inside Silicon Valley tends to center on personal optimization: supplements, biomarkers, resting heart rate. Halioua's argument for why aging drugs matter is different, and more structural.
"If, God forbid, our parents need to be in care, we can probably afford a home for them or support or nursing or whatever," she says. "the vast majority of people cannot. Some people, their parents get diagnosed with cancer and they have to stay at home. There's no choice. And they cannot take the opportunity to move to Silicon Valley."
The mechanism is the caretaking burden. It falls disproportionately on people without wealth and determines which career decisions they can make. Halioua notes she benefited directly: her parents' health gave her the freedom to build Loyal. For the majority of people, a parent's illness closes that door. A drug that extends healthy aging shifts who gets to take career risk and is a redistribution the longevity conversation rarely acknowledges.
About the Guest
Celine Halioua is founder and CEO of Loyal, a biotech company developing the first FDA-approved drugs for lifespan extension in dogs. She started Loyal after years working on the biology of aging, raising biotech pre-seed funding on a thesis the field considered regulatory impossible — that an FDA-approved drug for lifespan extension could exist. Loyal recently launched its first merch drop at merch.loyal.com, with all proceeds benefiting Muttville, the senior dog rescue.
About the Host
Sam Kirschner invests in ambitious early-stage founders building at the frontiers of science and tech. Village Global was an early investor in Loyal and is a first check investor in biotech startups.
